B&L to sue Alcon

Article

Bausch & Lomb is suing Alcon, claiming that it made false advertising claims about Bausch & Lomb's contact lens solution, ReNu MultiPlus.

Bausch & Lomb is suing Alcon, claiming that it made false advertising claims about Bausch & Lomb's contact lens solution, ReNu MultiPlus.

The company claims that Alcon's promotional use of a chart to demonstrate the safety of contact lens solutions could negatively influence patients and/or doctors. The chart shows the safety of different solutions based on corneal staining tests, rating them with a colour coding system: green is safe, yellow means use with caution and red indicates the solution is unsafe. Bausch & Lomb allege the chart has been produced without scientific studies or clinical evidence to back it up.

Alcon has yet to issue a statement regarding the claim.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.